PELI3 (Pellino E3 Ubiquitin Protein Ligase Family Member 3) is a member of the Pellino family of E3 ubiquitin ligases, which includes PELI1. PELI2. and PELI3. These proteins are evolutionarily conserved and play critical roles in regulating immune signaling pathways, particularly those involving Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs). PELI3 is involved in the ubiquitination process, a post-translational modification that influences protein stability, localization, and interactions. Unlike PELI1 and PELI2. which are well-studied in the context of innate immunity and inflammation, PELI3 has been less characterized but is implicated in modulating NF-κB and MAPK signaling pathways.
Antibodies targeting PELI3 are essential tools for studying its expression, function, and interaction networks in both physiological and pathological contexts. They enable researchers to investigate PELI3's role in immune regulation, apoptosis, and cellular stress responses. PELI3 dysregulation has been associated with diseases such as cancer, autoimmune disorders, and neurodegenerative conditions, making these antibodies valuable for translational research. Commercially available PELI3 antibodies are typically developed in rabbit or mouse hosts and validated for applications like Western blotting, immunohistochemistry, and immunoprecipitation. Specificity and cross-reactivity with other Pellino family members remain key considerations during experimental design. Ongoing studies aim to clarify PELI3's distinct mechanisms and therapeutic potential in disease models.